



Published in final edited form as:

*Tetrahedron Lett.* 2003 October 6; 44(41): 7659–7661. doi:10.1016/j.tetlet.2003.08.023.

## Synthetic studies of microtubule stabilizing agent peloruside A: an asymmetric synthesis of C<sub>10</sub>–C<sub>24</sub> segment

Arun K. Ghosh\* and Jae-Hun Kim

Department of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, Chicago, IL 60607, USA

### Abstract

An asymmetric synthesis of the C<sub>10</sub>–C<sub>24</sub> fragment of the potent antitumor macrolide, peloruside A is described. All three stereogenic centers have been enantioselectively constructed utilizing Evans alkylation, Brown asymmetric allylboration, and a substrate controlled epoxide formation. Other key reactions involved Grubbs's ring-closing olefin metathesis and Ando's *Z*-selective olefination reaction.

Peloruside A, a 16-membered macrolide, was recently isolated from the New Zealand marine sponge *Mycale hentscheli*.<sup>1</sup> It exhibited potent cytotoxicity against P388 murine leukemia cells with an IC<sub>50</sub> value of 10 ng/mL.<sup>1</sup> Like paclitaxel, peloruside A has shown microtubule-stabilizing activity and arrests cells in the G<sub>2</sub>-M phase.<sup>2</sup> It has structural resemblance to epothilones which are undergoing clinical trials.<sup>3</sup> Important antitumor activities of peloruside A along with its unique structural features have stimulated immense interest in the synthesis and structure–function studies. Peloruside A's initial structure and relative stereochemistry were established by NMR studies.<sup>1</sup> However, its absolute stereochemistry was conclusively established only recently after the first total synthesis<sup>4</sup> followed by its chemical and biological correlation with the natural peloruside A. To date, De Brabander and co-workers have reported the only total synthesis. Synthetic approaches toward fragments of peloruside A have been reported by Paterson et al.<sup>5</sup> We recently reported an enantioselective synthesis of the C<sub>1</sub>–C<sub>9</sub> segment of peloruside A.<sup>6</sup> In continuation of our on-going studies, we now report a stereocontrolled route to the C<sub>10</sub>–C<sub>24</sub> segment (**3**) of peloruside A where all three stereocenters have been created by asymmetric synthesis.

As shown in Figure 1, our convergent synthetic plan for peloruside A involves the assembly of C<sub>1</sub>–C<sub>9</sub> segment (**2**) and C<sub>10</sub>–C<sub>24</sub> (**3**) by an aldol reaction followed by a macrolactonization between the C<sub>15</sub>-hydroxyl group and the C<sub>1</sub>-carboxylic acid. We plan to synthesize the fragment **3** by a nucleophilic addition of isopropylmagnesium halide to the functionalized  $\delta$ -lactone derived from acrylate ester **4**. The corresponding homoallyl alcohol will be derived from protected alcohol **5** by oxidation, olefination and subsequent asymmetric allylboration of the resulting aldehyde utilizing Brown's protocol. Protected alcohol **5** will be readily available by Evans' asymmetric alkylation reaction.<sup>7</sup>

\*Corresponding author: arunghos@uic.edu.

As depicted in Scheme 1, asymmetric alkylation of chiral imide **6** was carried out with benzyloxymethyl chloride using Evans' protocol<sup>7a</sup> to provide the alkylated product **7** as a single isomer in 80% yield (from benzyloxazolidinone). Reduction of imide **7** by LiBH<sub>4</sub> in THF–MeOH at 23°C afforded alcohol **8**. Swern oxidation of **8** and subsequent Horner–Emmons reaction of the resulting aldehyde with sodium enolate of (*o*-cresol)<sub>2</sub>P=O(CH<sub>3</sub>)CHCO<sub>2</sub>Et as described by Ando<sup>8</sup> furnished tri-substituted *Z*-olefin **9** in 90% yield over two steps. The *Z*-selectivity was >99:1 as revealed by <sup>1</sup>H and <sup>13</sup>C NMR analysis. Our next synthetic plan was to install an α,β-unsaturated δ-lactone with appropriate stereochemistry and then elaborate the *syn*-1,3-diol functionality by a substrate-controlled diastereoselective epoxidation followed by reductive opening of the resulting epoxide. For the synthesis of α,β-unsaturated δ-lactone, ester **9** was first reduced by Dibal-H to deliver the corresponding alcohol. Dess–Martin periodinane oxidation provided the aldehyde which was subjected to the Brown asymmetric allylboration protocol<sup>9</sup> with allyldiisopinocampheylborane to afford homoallylic alcohol **10** as the major diastereomer (dr=93:7 by <sup>1</sup>H and <sup>13</sup>C NMR). Alcohol **10** was obtained in 65% yield over two steps after silica gel chromatography.

For synthesis of α,β-unsaturated δ-lactone, we relied upon ring-closing olefin metathesis protocol described in our recent work.<sup>10</sup> Reaction of **10** with acryloyl chloride and triethylamine at 0°C furnished acryloyl ester **11**. Exposure of **11** to a catalytic amount (10 mol%) of first generation commercial Grubb's catalyst<sup>11</sup> in CH<sub>2</sub>Cl<sub>2</sub> at reflux for 12 h provided α,β-unsaturated δ-lactone **12** in 83% yield after one recycle of the recovered starting material.<sup>12</sup> The use of titanium tetra-isopropoxide as a co-catalyst (40 mol%) significantly lowered the yield (62%) of δ-lactone **12**. Reaction with second generation Grubb's catalyst did not improve the overall yield (74%) either. For elaboration of the hydroxy γ-lactone with appropriate stereochemistry, δ-lactone **12** was exposed to nucleophilic epoxidation with alkaline hydrogen peroxide in methanol at 0°C to furnish the corresponding epoxide in 74% yield as a single isomer. Treatment of the resulting epoxide with diphenyldiselenide and sodium borohydride in 2-propanol afforded exclusively hydroxylactone **13** in quantitative yield.<sup>13</sup> Lactone **13** possesses the required *syn*-1,3-diol stereochemistry necessary for peloruside A synthesis. Protection of alcohol **13** under standard condition provided TBDPS ether **14** in quantitative yield.

For conversion of δ-lactone **14** to the C<sub>10</sub>–C<sub>24</sub> fragment, we first attempted direct opening of lactone ring with isopropylmagnesium chloride. However, reaction of **14** with excess isopropylmagnesium chloride under a variety of reaction conditions did not provide the desired ketone. In an alternative approach, δ-lactone **14** was transformed into C<sub>10</sub>–C<sub>24</sub> fragment ketone **16** as follows (Scheme 2). Reaction of **14** with *N,O*-dimethylhydroxylamine hydrochloride in the presence of trimethylaluminum in CH<sub>2</sub>Cl<sub>2</sub> according to Weinreb procedure<sup>14</sup> furnished the corresponding hydroxy Weinreb amide. Protection of the resulting alcohol as MEM-ether provided Weinreb amide **15** in 86% yield (from **14**). Treatment of **15** with isopropylmagnesium chloride (5 equiv.) in THF at 23°C for 5 h afforded C<sub>10</sub>–C<sub>24</sub> fragment ketone **16**<sup>15</sup> in 61% yield. It turned out that both MEM- and TBDPS-protecting groups were critical to form **16**. Replacement of the MEM-group with a PMB-group resulted in substantial β-elimination as well as degradation of starting material.

In summary, a highly stereoselective synthesis of C<sub>10</sub>–C<sub>24</sub> segment of peloruside A has been accomplished. The key steps involved an Evans asymmetric alkylation, Ando's *Z*-selective olefination, Brown asymmetric allylboration, Grubbs's ring-closing olefin metathesis, and substrate controlled stereoselective epoxidation. Work toward the total synthesis of peloruside A is in progress.

## Acknowledgements

Partial financial support for this work was provided by the National Institutes of Health.

## References

1. West LM; Northcote PT J. Org. Chem 2000, 65, 445. [PubMed: 10813954]
- 2 (a). Hood KA; Backstorm BT; West LM; Northcote PT; Berridge MV; Miller JH Anti-Cancer Drug Design 2001, 16, 155; [PubMed: 11962513] (b)Hood KA; West LM; Rouwe B; Northcote PT; Berridge MV; St. Wakefield J; Miller JH Cancer Res. 2002, 62, 3356. [PubMed: 12067973]
- 3 (a). Bollag DM; McQueney PA; Zhu J; Hensens O; Koupal L; Liesch J; Goetz M; Lazarides E; Woods CM Cancer Res. 1995, 55, 2325; [PubMed: 7757983] (b)Nicolaou KC; Rosechagner F; Vourloumis D Angew. Chem 1998, 37, 2014; [PubMed: 29711063] (c)Stachel SJ; Biswas K; Danishefsky SJ Curr. Pharm. Des 2001, 7, 1277 and references cited therein. [PubMed: 11472267]
4. Liao X; Wu Y; De Brabander JK Angew. Chem., Int. Ed 2003, 42, 1648.
5. Paterson I; Di Francesco ME; Kuhn T Org. Lett 2003, 5, 599. [PubMed: 12583779]
6. Ghosh AK; Kim J-H Tetrahedron Lett 2003, 44, 3967. [PubMed: 30393410]
- 7 (a). Evans DA; Chapman KT; Huang DT; Kawaguchi AT Angew. Chem., Int. Ed. Engl 1987, 26, 1184;(b)Evans DA; Urpi F; Somers TC; Cleark JS; Bilodeau MT J. Am. Chem. Soc 1990, 112, 8215;(c)Ihara M; Katsumata A; Setsu F; Tokunaga Y; Fukumoto KJ. Org. Chem 1996, 61, 677. [PubMed: 11666991]
8. Ando KJ. Org. Chem 1998, 63, 8411.
- 9 (a). Jadhav PK; Bhat KS; Perumaal T; Brown HC J. Org. Chem 1986, 51, 432;(b)Racgerlaa US; Brown HC J. Org. Chem 1991, 56, 401.
- 10 (a). Ghosh AK; Cappiello J; Shin D Tetrahedron Lett. 1998, 39, 4651;(b)Ghosh AK; Liu C Chem. Commun 1999, 1743;(c)Ghosh AK; Wang YJ. Am. Chem. Soc. 2002, 122, 11027;(d)Ghosh AK; Wang Y; Kim JT J. Org. Chem 2001, 66, 8973. [PubMed: 11749630]
11. Grubbs RH; Chang S Tetrahedron 1998, 54, 4413.
12. Initially, lactone **12** was obtained in 68% along with 23% of unreacted starting material. After one recycling of starting material overall isolated yield was 83%.
- 13 (a). Ghosh AK; Lei H J. Org. Chem 2000, 65, 4779; [PubMed: 10959897] (b)Ghosh AK; Lei H Synthesis 2002, 371.
14. Basha A; Lipton M; Weinreb SM Tetrahedron Lett. 1977, 18, 4171.
15. All new compounds gave satisfactory spectroscopic and analytical results. **16**:  $[\alpha]_D^{20} = +87.5$  (c 0.4, CHCl<sub>3</sub>); IR (thin film) 2932, 1713, 1429, 1039 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.72–7.67 (m, 4H), 7.42–7.26 (m, 11H), 5.06 (d, *J*=10.3 Hz, 1H), 4.54 (m, 1H), 4.49–4.42 (m, 4H), 4.34 (d, *J*=6.8 Hz, 1H), 3.57 (m, 1H), 3.43–3.27 (m, 8H), 2.75 (dd, *J*=16.0, 4.6 Hz, 1H), 2.63 (dd, *J*=6.0, 7.3 Hz, 1H), 2.59–2.52 (m, 2H), 1.95 (m, 1H), 1.56 (m, 1H), 1.46 (m, 1H), 1.42 (d, *J*=0.9 Hz, 3H), 1.15 (m, 1H), 1.06–1.01 (m, 15H), 0.79 (t, *J*=7.5 Hz, 3H); <sup>13</sup>C NMR (125 MHz)  $\delta$  213.2, 139.2, 136.4, 136.3, 135.6, 134.3, 131.5, 130.0, 129.9, 128.7, 127.9, 127.8 (2C), 92.5, 74.2, 73.3, 72.2, 70.5, 68.4, 67.6, 59.4, 46.9, 42.1, 41.1, 39.5, 27.4 (3C), 25.4, 19.7, 18.3, 18.2, 12.1; HRMS (ESI) *m/z* calcd for C<sub>42</sub>H<sub>60</sub>O<sub>6</sub>Si (M<sup>+</sup>+Na) 711.4057, found 711.4045.






Figure 1.

**Scheme 1. Reagents and conditions:**

(a)  $\text{TiCl}_4$ ,  $\text{Et}_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $\text{PhCH}_2\text{OCH}_2\text{Cl}$ ,  $0^\circ\text{C}$ , 1.5 h; (b)  $\text{LiBH}_4$ ,  $\text{MeOH}$ ,  $\text{THF}$ ,  $23^\circ\text{C}$ , 1 h (94%); (c)  $(\text{COCl})_2$ ,  $\text{DMSO}$ ,  $\text{Et}_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $-60^\circ\text{C}$ , 45 min; (d)  $(o\text{-cresol})_2\text{P}(\text{O})(\text{CH}_2\text{CHCO}_2\text{Et})$ ,  $\text{NaH}$ ,  $\text{THF}$ ,  $-78$  to  $-20^\circ\text{C}$ , 2 h (90% over two steps); (e) Dibal-H,  $\text{CH}_2\text{Cl}_2$ ,  $-78^\circ\text{C}$  to  $-40^\circ\text{C}$ , 1 h (96%); (f) Dess–Martin periodinane,  $\text{NaHCO}_3$ ,  $\text{CH}_2\text{Cl}_2$ ,  $23^\circ\text{C}$ , 1.5 h; (g)  $\text{CH}_2\text{CHCH}_2\text{B}[(+)\text{-Ipc}]_2$ ,  $\text{Et}_2\text{O}$ ,  $-80^\circ\text{C}$ , 3 h (65% over two steps); (h)  $\text{CH}_2\text{CHCOCl}$ ,  $\text{Et}_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ , 2 h (77%); (i)  $\text{Cl}_2(\text{Pcy})_2\text{RuCHPh}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $40^\circ\text{C}$ , 12 h (83%); (j)  $\text{H}_2\text{O}_2$ , 6N-aq  $\text{NaOH}$ ,  $\text{MeOH}$ , 1.5 h (74%); (k)  $\text{NaBH}_4$ ,  $\text{PhSeSePh}$ ,  $\text{AcOH}$ ,  $t\text{-PrOH}$ ,  $0^\circ\text{C}$ , 30 min (quant.); (l)  $\text{TBDPSCl}$ , imidazole,  $\text{DMAP}$ ,  $\text{DMF}$ ,  $23^\circ\text{C}$ , 13 h (quant.).

**Scheme 2. Reagent and conditions:**

(a)  $\text{AlMe}_3$ ,  $\text{HN}(\text{OCH}_3)\text{-CH}_3\cdot\text{HCl}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $23^\circ\text{C}$ , 2.5 h (93%); (b)  $\text{MEMCl}$ ,  $\text{DIPEA}$ ,  $23^\circ\text{C}$ , 9 h (92%); (c)  $^i\text{PrMgCl}$ ,  $\text{THF}$ ,  $23^\circ\text{C}$ , 5 h (61%).